Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

LOGC & PAYS INVESTOR NOTIFICATION: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm

PAYS

NEW YORK, NY / ACCESSWIRE / April 22, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

LogicBio Therapeutics, Inc.(NASDAQ: LOGC)

Class Period: December 3, 2018 - February 10, 2020

Deadline: May 18, 2020
For more info:www.bgandg.com/logc

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements that: (1) LogicBio Therapeutics, Inc.'s behind-schedule and rushed Investigational New Drug ("IND") submission of LB-001 did not answer certain pertinent clinical and nonclinical questions; (2) as a result, the U.S. Food and Drug Administration was likely to hold or deny the IND submission of LB-001 for treatment of methylmalonic acidemia (MMA); and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Paysign, Inc. (NASDAQ: PAYS)

Class Period: March 12, 2019 - March 15, 2020

Deadline: May 18, 2020
For more info:www.bgandg.com/pays

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements that: (1) Paysign's internal control over financial reporting was not effective; (2) Paysign's information technology general controls were not effective; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/585776/LOGC-PAYS-INVESTOR-NOTIFICATION-Bronstein-Gewirtz-Grossman-LLC-Updates-Investors-of-Class-Actions-and-Encourages-Investors-to-Contact-the-Firm